Anaemia of chronic disease in rheumatoid arthritis: In vivo effects of tumour necrosis factor α blockade

British Journal of Rheumatology

Volumn 36, Issue 9, 1997, Pages 950-956

  Davis, D ^a   Charles, P J ^a   Potter, A ^a   Feldmann, M ^a   Maini, R N ^a   Elliott, M J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anaemia of chronic disease; Erythropoietin; Haemoglobin; Interleukin 6; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ERYTHROPOIESIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANEMIA; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; INTERLEUKIN-6; MALE; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030881463     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Remacha AF, Rodriguez-De La Serna A, Garcia-Die F, Geli C, Diaz C, Gimferrer E. Erythroid abnormal-ities in rheumatoid arthritis: the role of erythropoietin. J Rheumatol 1992;19:1687-91.
2. Weber J, Werre JM, Julius HW, Marx JJM. Decreased iron absorption in patients with active rheumatoid arthritis, with and without iron deficiency. Ann Rheum Dis 1988;47:404-9.
3. Bentley DP, Cavill I, Ricketts C, Peake S. A method for the investigation of reticuloendothelial iron kinetics in man. Br J Haematol 1979;43:619-24.
4. Baer AN, Dessypris EN, Goldwasser E, Krantz SB. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol 1987;66:559-64.
5. 12, and folic acid deficiency, and erythropoietin responsiveness. Ann Rheum Dis 1990;49:93-8.
6. Boyd HK, Lappin TR, Bell AL. Evidence for impaired erythropoietin response to anaemia in rheumatoid disease. Br J Rheumatol 1991;30:255-9.
7. Kling PJ, Dragsten PR, Roberts RA et al. Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy. Br J Haematol 1996;95:241-8.
8. Means RT Jr, Olsen NJ, Krantz ST et al. Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arthritis Rheum 1989;32:638-42.
9. Pincus T, Olsen NJ, Russell IJ et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990;89:161-8.
10. Gudbjörnsson B, Hällgren R, Wide L, Birgegärd G. Response of anaemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin. Ann Rheum Dis 1992;51:747-52.
11. Jongen-Lavrencic M, Peeters HRM, Backx B, Touw IP, Vreugdenhil G, Swaak AJG. R-h-erythropoietin counteracts the inhibition of in vitro erythropoiesis by tumour necrosis factor alpha in patients with rheumatoid arthritis. Rheumatol Int 1994;14:109-13.
12. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;ii:1175-8.
13. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8.
14. Schreiber S, Howaldt S, Schnoor M et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996;334:619-23.
15. Pettersson T, Rosenlöf K, Friman C, Mickos A, Teppo A-M, Fyhrquist F. Successful treatment of the anemia of rheumatoid arthritis with subcutaneously administered recombinant human erythropoietin. Scand J Rheumatol 1993;22:188-93.
16. Mamus SW, Beck-Schroeder S, Zanjani ED. Suppression of normal human erythropoiesis by gamma interferon in vitro. J Clin Invest 1985;75:1496-503.
17. Means RT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by γ interferon can be corrected by recombinant human erythropoietin. Blood 1991;78:2564-7.
18. Alvarez-Hernandez X, Liceaga J, McKay IC, Brock JH. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 1989;61:319-22.
19. Johnson RA, Waddelow TA, Caro J, Oliff A, Roodman GD. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989;74:130-8.
20. Akahane K, Hosoi T, Urabe A, Kawakami M, Takaku F. Effects of recombinant human tumor necrosis factor (rhTNF) on normal human and mouse hemopoietic progenitor cells. Int J Cell Clon 1987;5:16-26.
21. Roodman GD. Mechanisms of erythroid suppression in the anemia of chronic disease. Blood Cells 1987;13:171-84.
22. Rusten LS, Jacobsen SEW. Tumor necrosis factor (TNF)-α directly inhibits human erythropoiesis in vitro: Role of p55 and p75 TNF receptors. Blood 1995;85:989-96.
23. Zhang Y, Harada A, Bluethmann H et al. Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: increase of early hematopoietic progenitor cells in TNF receptor p55-deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNGα in vitro. Blood 1995;86:2930-7.
24. Johnson CS, Cook CA, Furmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor-α (TNFα): reversal with exogenous erythropoietin (EPO). Exp Hematol 1990;18:109-13.
25. Vreugdenhil G, Löwenberg B, Van Eijk HG, Swaak AJG. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest 1992;22:488-93.
26. Stockenhuber F, Keil M, Wurnig C, Kurz RW, Gottsauner-Wolf M, Balcke P. Impaired erythropoietin responsiveness in anaemic rheumatoid arthritis patients: potential relation to immune mechanisms. Clin Sci 1994;86:633-8.
27. Burstein SA, Downs T, Friese P et al. Thrombocytopoiesis in normal and sublethally irradiated dogs: Response to human interleukin-6. Blood 1992;80:420-8.
28. Weber J, Yang JC, Topalian SL et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993;11:499-506.
29. van Gameren MM, Willemse PHB, Mulder NH et al. Effects of recombinant human interleukin-6 in cancer patients: A phase I-II study. Blood 1994;5:1434-41.
30. Atkins MB, Kappler K, Mier JW, Isaacs RE, Berkmann EM. Interleukin-6-associated anemia: determination of the underlying mechanism. Blood 1995;86:1288-91.
31. Vreugdenhil G, Löwenberg B, van Eijk HG, Swaak AJG. Anaemia of chronic disease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levels and effect of IL-6 and anti-IL-6 on in vitro erythropoiesis. Rheumatol Int 1990;10:127-30.
32. Maury CPJ, Andersson LV, Teppo A-M, Partanen S, Juvonen E. Mechanism of anaemia in rheumatoid arthritis: demonstration of raised interleukin 1β concentrations in anaemic patients and on interleukin 1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukaemia (HEL) cells in vitro. Ann Rheum Dis 1988;47:972-8.
33. Schooley JC, Kullgren B, Allison AC. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Haematol 1987;67:11-7.
34. Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P. In vivo hematopoietic effects of recombinant interleukin-1α in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis and reversal of erythroid suppression with erythropoietin. Blood 1989;73:678-83.
35. Smith MA, Knight SM, Maddison PJ, Smith JG. Anaemia of chronic disease in rheumatoid arthritis: effect of the blunted response to erythropoietin and of interleukin 1 production by marrow macrophages. Ann Rheum Dis 1992;51:753-7.
36. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-bind comparison of chimeric monoclonal anti-body to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
37. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
38. Vreugdenhil G, Baltus CAM, van Eijk HG, Swaak AJG. Anaemia of chronic disease: Diagnostic significance of erythrocyte and serological parameters in iron deficient rheumatoid arthritis patients. Br J Rheumatol 1990;29:105-10.
39. Hansen TM, Hansen NE, Birgens HS, Hölund B, Lorenzen I. Serum ferritin and the assessment of iron deficiency in rheumatoid arthritis. Scand J Rheumatol 1983;12:353-9.
40. Maini RN, Elliott MJ, Brennan FM, Williams RO. Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995;144:195-223.
41. Bondurant MC, Koury MJ. Anaemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol Cell Biol 1986;6:2731-3.
42. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 1988;73:449-55.
43. Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992;31:653-61.
44. Deleuran BW, Chu C-Q, Field M et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1992;35:1170-8.
45. Cooper WO, Fava RA, Gates CA, Cremer MA, Townes AS. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 1992;89:244-50.
46. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
47. Kendall R, Wasti A, Harvey A et al. The relationship of haemoglobin to serum erythropoietin concentrations in the anaemia of rheumatoid arthritis: the effect of oral prednisolone. Br J Rheumatol 1993;32:204-8.
48. Waage A, Bakke O. Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 1988;63:299-302.
49. Kern JA, Lamb RJ, Reed JC, Daniele RP, Nowell PC. Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms. J Clin Invest 1988;81:237-44.
50. Wolfe F, Mitchell DA, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
51. Blake DR, Hall ND, Bacon PA, Halliwell B, Gutteridge JMC. The importance of iron in rheumatoid disease. Lancet 1981;2:1142-4.